FDA PCAC Review of Seven Peptide-Related Bulk Drug Substances: July 23–24, 2026

The U.S. Food and Drug Administration's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to discuss seven peptide-related groups of bulk drug substances on July 23 and 24, 2026. The substances are BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, and Epitalon, with both the free-base and acetate forms considered separately where listed. [1]

The meeting is important, but it is easy to describe incorrectly. It is not a drug-approval meeting, and placement on the Section 503A Bulks List would not make any of these substances FDA-approved drugs. PCAC provides advice to FDA about whether nominated bulk drug substances are appropriate for use in certain compounded drug products. FDA says it will not make a final determination until it has considered the committee process and completed its reviews. [2]

Current Status

Item	Status as of July 21, 2026
PCAC meeting	Scheduled for July 23–24, 2026
FDA staff position	FDA proposes that all 14 substance/form combinations not be added to the 503A Bulks List
PCAC recommendation	Not yet available
FDA final determination	Not yet issued
FDA drug approval	None of the seven is being considered for approval at this meeting
Last checked	July 21, 2026

FDA's meeting-level briefing document states that agency staff are proposing not to include the free-base or acetate form of any of the seven peptide-related substances. The committee will discuss those proposals and provide advice; that advice is not itself the final agency action. [2]

What Is PCAC?

The Pharmacy Compounding Advisory Committee advises FDA on scientific, technical, and medical issues involving drug compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Its members review FDA analyses, nomination materials, public comments, and presentations before voting or otherwise giving recommendations.

Advisory committees do not replace FDA's decision-making authority. A PCAC vote can influence the agency's next step, but FDA may consider additional evidence and legal or policy issues after the public meeting.

What Is Section 503A?

Section 503A describes conditions under which qualifying patient-specific compounded drugs may receive exemptions from several requirements that ordinarily apply to commercially manufactured drugs. It is not a pathway for approving a drug.

FDA explains that a pharmacist or physician operating under Section 503A may compound from a bulk drug substance only under specified conditions. In broad terms, the substance must comply with an applicable USP or NF monograph, be a component of an FDA-approved drug when no applicable monograph exists, or appear on the FDA's 503A Bulks List. Other conditions also apply, including requirements involving the source of the bulk substance and a valid certificate of analysis. [3]

This distinction matters:

FDA approval evaluates a finished drug for a defined indication, formulation, manufacturing process, labeling, and benefit-risk profile.
503A Bulks List inclusion addresses whether a bulk drug substance may be used in qualifying compounding when other statutory conditions are met.
PCAC review gives FDA expert advice during development of the bulks list.

None of those terms is interchangeable.

Which Substances Are Being Reviewed?

FDA divided the meeting across two days and identified the uses it evaluated for each substance. The agency is evaluating the listed free-base and acetate forms as distinct bulk drug substances.

Date	Substance group	Use or uses FDA evaluated	Research profile
July 23	BPC-157	Ulcerative colitis	BPC-157 research
July 23	KPV	Wound healing and inflammatory conditions	KPV research
July 23	TB-500	Wound healing	TB-500 research
July 23	MOTS-c	Obesity and osteoporosis	MOTS-c research
July 24	Emideltide (DSIP)	Opioid withdrawal, chronic insomnia, and narcolepsy	Emideltide research
July 24	Semax	Cerebral ischemia, migraine, and trigeminal neuralgia	Semax research
July 24	Epitalon	Insomnia	Epitalon research

The evaluated uses do not represent every claim made about these peptides online. They reflect the uses FDA found sufficiently defined for this review. For example, FDA's BPC-157 document says it did not evaluate several other nominated uses because the nomination lacked enough information and FDA did not identify relevant clinical studies. [4]

What Do the FDA Briefing Documents Say?

FDA applies four criteria when evaluating a substance for the 503A Bulks List: physical and chemical characterization, safety issues, available evidence of effectiveness or lack of effectiveness, and historical use in compounded drug products. The criteria are balanced rather than treated as a single pass-or-fail test. [2]

Across the seven reviews, several themes recur:

Characterization and product quality

FDA identified inconsistent naming, uncertainty about whether nominations referred to free-base or acetate forms, and missing or inadequate information about identity, purity, peptide-related impurities, aggregates, microbial quality, or dosage-form performance. These concerns are especially relevant for peptides because formulation, manufacturing, storage, and aggregation can alter quality and potential immunogenicity.

Human evidence

The evidence varies by substance, but it is generally limited. FDA reported no human administration data for KPV, TB-500, or MOTS-c in the reviewed literature. [5][6][10] Emideltide has older small human studies, but FDA described the effectiveness evidence as insufficient and the study methods as inconsistent or preliminary. [7] Semax has some human literature, much of it from a limited research setting, while FDA still concluded that the overall balance weighed against listing. [9]

Safety uncertainty

An absence of reported adverse events does not establish safety. FDA repeatedly noted limited surveillance, lack of clinical exposure data, unknown long-term risks, and potential concerns related to impurities, aggregation, and immune responses. The individual briefing documents should be read as regulatory evidence reviews, not as clinical treatment guidance.

FDA's proposal

FDA staff concluded that the available information weighs against adding every reviewed free-base and acetate form to the 503A Bulks List. [2] That is the agency's proposal going into the meeting, not the committee's recommendation and not yet a final rule or final determination.

Why This Is Not an Approval Meeting

Drug approval would require a sponsor to submit a marketing application supported by evidence for a specific product, indication, dose, route, manufacturing process, and labeling. PCAC is instead considering whether bulk substances should appear on a statutory list used in pharmacy compounding.

Even if PCAC recommended inclusion and FDA later added a substance to the list, that would not establish a favorable clinical benefit-risk profile for a disease, authorize general commercial marketing, or convert products sold online as “research peptides” into approved medicines.

Likewise, a recommendation against inclusion would address eligibility for the Section 503A framework. It would not erase the underlying preclinical literature, and it would not substitute for a substance-specific enforcement or approval analysis in every other legal context.

What Could Happen After the Meeting?

The immediate output is expected to be committee advice, commonly expressed through discussion and votes on the questions FDA presents. Afterward:

Meeting video, minutes, vote results, and transcripts may be posted.
FDA will evaluate the committee's recommendations and any remaining evidence.
FDA may proceed through the regulatory process needed to add or exclude substances from the 503A Bulks List.
A final determination may differ from the preliminary staff proposal or committee recommendation.

There is no guaranteed date for a final determination. This page will be updated rather than replaced so the regulatory record remains in one location.

Meeting Outcome

Pending. The meeting has not occurred as of the last update on July 21, 2026.

What Changed

July 21, 2026: FDA's individual briefing packages and meeting-level questions were reviewed. FDA staff propose not adding any of the 14 free-base or acetate substance entries under discussion.

Next Regulatory Steps

The next concrete step is the PCAC meeting on July 23–24. After the meeting, this section will be updated with the committee's votes or recommendations, the principal points of disagreement, and any timeline FDA provides for further action.

What Researchers Should Understand

The briefing packages are valuable because they separate laboratory findings, limited clinical observations, product-quality questions, and marketing claims. They also illustrate why a mechanistic result in an in vitro model or animal study cannot establish clinical effectiveness.

Researchers reading the documents should ask:

Was the exact chemical form identified?
Was the tested material the same substance described by compounders?
Were studies conducted in humans or only in cells and animals?
Did the study evaluate the same route and use under review?
Are adverse-event data meaningful given underreporting and limited exposure?
Were the results independently replicated?

Our guides to reading peptide research, evaluating peptide claims, and understanding clinical trials provide additional context.

Frequently Asked Questions

Did FDA ban these seven peptides?

The July 23–24 meeting itself is not a ban. FDA staff are proposing that the reviewed forms not be placed on the 503A Bulks List, and PCAC has not yet made its recommendations. The legal significance of a later final agency action should be described only after FDA completes that process.

Are these peptides FDA approved?

No. The meeting is not considering new drug applications for these substances. A compounding-list decision is different from FDA approval of a finished drug.

Does 503A listing prove a peptide works?

No. List placement would concern eligibility for qualifying compounding under Section 503A. It would not establish the safety or effectiveness of a finished product for a particular condition.

Why are free-base and acetate forms listed separately?

FDA treats them as distinct bulk drug substances because their chemical and physical characteristics may differ. The meeting questions therefore address each form separately.

When will the final answer be known?

FDA has not provided a guaranteed date for its final determination. The committee meeting is one step in the process, followed by agency review and any required regulatory action.